Streetbeat News

Regulatory

KROS

Keros Therapeutics has received FDA Fast Track Designation for KER-050, aimed at treating lower-risk Myelodysplastic Syndromes. This designation is expected to expedite the development and review process for KER-050, potentially bringing it to market more quickly.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 12:03 pm

AAPL

Apple Inc.'s iOS 17.4 update, in compliance with the EU's Digital Markets Act, has led to a significant increase in users for Mozilla Firefox and Brave browsers in the EU. Firefox saw a more than 50% rise in users in Germany and a nearly 30% increase in France. Brave also experienced a surge in users after the update allowed for the selection of default browsers. The update introduced changes like alternative app marketplaces and third-party browser engine support, exclusively in the EU.

Portfolio Pulse from Ananya Gairola

March 14, 2024 | 12:02 pm

MIRM

Mirum Pharmaceuticals' shares surged following the FDA's approval of LIVMARLI oral solution for treating cholestatic pruritus in patients aged five and older with progressive familial intrahepatic cholestasis. Additionally, HC Wainwright reaffirmed a Buy rating on MIRM and increased its price target from $45 to $58.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:54 am

LAC

Lithium Americas' stock is up following the announcement of a conditional $2.26 billion loan from the U.S. Department of Energy. This loan, part of the Advanced Technology Vehicles Manufacturing Loan Program, is aimed at financing the construction of processing facilities at Thacker Pass, Nevada.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:45 am

PROP

Prairie Operating has received approval from the Colorado Energy and Carbon Management Commission for its Genesis I Oil & Gas Development Plan. This marks a significant step forward for the company's operations in the region.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:33 am

CYBN

Cybin Inc. announced a positive End-of-Phase 2 meeting with the FDA for CYB003, a deuterated psilocybin analog for treating Major Depressive Disorder. The company is now preparing for a Phase 3 program.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:32 am

RNLX

Renalytix has announced that its KidneyIntelX in-vitro diagnostic test has been included in the final KDIGO 2024 Clinical Practice Guideline for the evaluation and management of chronic kidney disease. This inclusion represents a significant endorsement of the KidneyIntelX test and could potentially increase its adoption in clinical settings.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:18 am

TLRY

Tilray Brands has received approval for the first medical cannabis extract in Portugal, marking a significant milestone in the company's expansion in the European market. This approval could potentially increase Tilray's market share and revenue in the region.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 11:16 am

BABA

GOOGL

META

MSFT

SNAP

The EU Commission has initiated an investigation into Alibaba's AliExpress over concerns regarding the sale of illegal products, pornographic materials, and the presence of hidden links on its platform. The investigation also seeks information from online platforms about generative AI.

Portfolio Pulse from Charles Gross

March 14, 2024 | 10:53 am

PBR

Petrobras has addressed recent media speculation by stating there is no ongoing study to create a new reserve. The company emphasized that any material facts will be disclosed to the market in due course.

Portfolio Pulse from Charles Gross

March 14, 2024 | 10:14 am